The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis
Abstract
Miltefosine is an alkylphosphocholine drug with demonstrated activity against various parasite species and cancer cells as well as some pathogenic bacteria and fungi. For 10 years it has been licensed in India for the treatment of visceral leishmaniasis (VL), a fatal neglected parasitic disease. It is the first and still the only oral drug that can be used to treat VL and cutaneous leishmaniasis (CL). The standard 28 day miltefosine monotherapy regimen is well tolerated, except for mild gastrointestinal side effects, although its teratogenic potential severely hampers its general use in the clinic and roll-out in national elimination programmes. The pharmacokinetics of miltefosine are mainly characterized by its long residence time in the body, resulting in extensive drug accumulation during treatment and long elimination half-lives. At the moment, different combination therapy strategies encompassing miltefosine are being tested in multiple controlled clinical trials in various geographical areas of endemicity, both in South Asia and East Africa. We here review the most salient pre-clinical and clinical pharmacological aspects of miltefosine, its mechanism of action against Leishmania parasites and other pathogens, and provide a systematic overview of the efficacy and safety data from all clinical trials of miltefosine, either alone or in combination, in the treatment of VL and CL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Murray, H. W., Berman, J. D., Davies, C. R., & Saravia, N. G. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67629-5 · Cited by 1,771
INDIAN JOURNAL OF MEDICAL RESEARCH.
(1931) · The Lancet · doi:10.1016/s0140-6736(00)82268-0 · Cited by 1,632
Bulletin of the World Health Organization
(2006) · Bulletin of the World Health Organization · doi:10.2471/blt.00.00000 · Cited by 1,602
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control?
Chappuis, F., Sundar, S., Hailu, A., Ghalib, H., Rijal, S., Peeling, R. W., Alvar, J., & Boelaert, M. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1748 · Cited by 1,490
Oral Miltefosine for Indian Visceral Leishmaniasis
Sundar, S., Jha, T. K., Thakur, C. P., Engel, J., Sindermann, H., Fischer, C., Junge, K., Bryceson, A., & Berman, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021556 · Cited by 779
Sundar, S., More, D. K., Singh, M. K., Singh, V. P., Sharma, S., Makharia, A., Kumar, P. C. K., & Murray, H. W. (2000) · Clinical Infectious Diseases · doi:10.1086/318121 · Cited by 664
Miltefosine, an Oral Agent, for the Treatment of Indian Visceral Leishmaniasis
Jha, T. K., Sundar, S., Thakur, C. P., Bachmann, P., Karbwang, J., Fischer, C., Voss, A., & Berman, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912093412403 · Cited by 468
Single-Dose Liposomal Amphotericin B for Visceral Leishmaniasis in India
Sundar, S., Chakravarty, J., Agarwal, D., Rai, M., & Murray, H. W. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0903627 · Cited by 434
Miltefosine for New World Cutaneous Leishmaniasis
Soto, J., Arana, B. A., Toledo, J., Rizzo, N., Vega, J. C., Diaz, A., Luz, M., Gutierrez, P., Arboleda, M., Berman, J. D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/383321 · Cited by 385
Bern, C., Adler‐Moore, J., Berenguer, J., Boelaert, M., Boer, M. D., Davidson, R. N., Figueras, C., Gradoni, L., Kafetzis, D. A., Ritmeijer, K., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/507530 · Cited by 345
Sundar, S., Sinha, P. K., Rai, M., Verma, D. K., Nawin, K., Alam, S., Chakravarty, J., Vaillant, M., Verma, N., Pandey, K., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62050-8 · Cited by 337
Self-citationCombination therapy for visceral leishmaniasis
van Griensven, J., Balasegaram, M., Meheus, F., Alvar, J., Lynen, L., & Boelaert, M. (2010) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70011-6 · Cited by 336
Self-citationPhase 4 Trial of Miltefosine for the Treatment of Indian Visceral Leishmaniasis
Bhattacharya, S. K., Sinha, P. K., Sundar, S., Thakur, C. P., Jha, T. K., Pandey, K., Das, V. R., Kumar, N., Lal, C., Verma, N., et al. (2007) · The Journal of Infectious Diseases · doi:10.1086/519690 · Cited by 261
Trial of oral miltefosine for visceral leishmaniasis
Sundar, S., Rosenkaimer, F., Makharia, M. K., Goyal, A. K., Mandal, A. K., Voss, A., Hilgard, P., & Murray, H. W. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04367-0 · Cited by 244
Hydrogen peroxide induces apoptosis-like death in Leishmania donovani promastigotes
Das, M., Mukherjee, S. B., & Shaha, C. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.13.2461 · Cited by 237
Treatment of American Cutaneous Leishmaniasis with Miltefosine, an Oral Agent
Soto, J., Toledo, J., Gutierrez, P., Nicholls, R. S., Padilla, J., Engel, J., Fischer, C., Voss, A., & Berman, J. (2001) · Clinical Infectious Diseases · doi:10.1086/322689 · Cited by 227
Sundar, S., Rai, M., Chakravarty, J., Agarwal, D., Agrawal, N., Vaillant, M., Olliaro, P., & Murray, H. W. (2008) · Clinical Infectious Diseases · doi:10.1086/591972 · Cited by 209
In Vitro and In Vivo Interactions between Miltefosine and Other Antileishmanial Drugs
Seifert, K., & Croft, S. L. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.1.73-79.2006 · Cited by 207
Chunge, C. N., Owate, J., Pamba, H. O., & Donno, L. (1990) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(90)90263-e · Cited by 175
van Blitterswijk, W., & Verheij, M. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208785294636 · Cited by 171
Jha, T. K., Olliaro, P., Thakur, C. P. N., Kanyok, T. P., Singhania, B. L., Singh, I. J., Singh, N. K. P., Akhoury, S., Jha, S., & Lockwood, D. N. J. (1998) · BMJ · doi:10.1136/bmj.316.7139.1200 · Cited by 170
van der Luit, A. H., Budde, M., Ruurs, P., Verheij, M., & van Blitterswijk, W. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203176200 · Cited by 164
Miltefosine Affects Lipid Metabolism in Leishmania donovani Promastigotes
Rakotomanga, M., Blanc, S., Gaudin, K., Chaminade, P., & Loiseau, P. M. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01123-06 · Cited by 163
Pharmacokinetics of Miltefosine in Old World Cutaneous Leishmaniasis Patients
Dorlo, T. P. C., van Thiel, P. P. A. M., Huitema, A. D. R., Keizer, R. J., de Vries, H. J. C., Beijnen, J. H., & de Vries, P. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00014-08 · Cited by 160
Self-citationWidmer, F., Wright, L. C., Obando, D., Handke, R., Ganendren, R., Ellis, D. H., & Sorrell, T. C. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.2.414-421.2006 · Cited by 146
Efficacy and Tolerability of Miltefosine for Childhood Visceral Leishmaniasis in India
Bhattacharya, S., Jha, T. K., Sundar, S., Thakur, C. P., Engel, J., SINDERMANN, H., Junge, K., Karbwang, J., Bryceson, A. D. M., & Berman, J. D. (2004) · Clinical Infectious Diseases · doi:10.1086/380638 · Cited by 145
D-21266, a New Heterocyclic Alkylphospholipid with Antitumour Activity
Hilgard, P., Klenner, T., Stekar, J., Nössner, G., Kutscher, B., & Engel, J. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00466-2 · Cited by 144
Treatment of Bolivian Mucosal Leishmaniasis with Miltefosine
Soto, J., Toledo, J. T., Valda, L., Balderrama, M., Rea, I., Parra, R. S. L., Ardiles, J. H., Soto, P., Gomez, A., Molleda, F., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/510588 · Cited by 139
Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy
Chugh, P., Bradel-Tretheway, B., Monteiro-Filho, C. M., Planelles, V., Maggirwar, S. B., Dewhurst, S., & Kim, B. (2008) · Retrovirology · doi:10.1186/1742-4690-5-11 · Cited by 138
Pérez-Victoria, J. M., Pérez-Victoria, F. J., Parodi-Talice, A., Jiménez, I., Ravelo, Á., Castanys, S., & Gamarro, F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.9.2468-2474.2001 · Cited by 135
Rakotomanga, M., Saint-Pierre-Chazalet, M., & Loiseau, P. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.7.2677-2686.2005 · Cited by 133
Meheus, F., Balasegaram, M., Olliaro, P., Sundar, S., Rijal, S., Faiz, M. A., & Boelaert, M. (2010) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000818 · Cited by 131
Self-citationMiltefosine Promotes IFN-γ-Dominated Anti-Leishmanial Immune Response
Wadhone, P., Maiti, M., Agrawal-Rajput, R., Kamat, V., Martin, S., & Saha, B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803859 · Cited by 125
Seaman, J., Pryce, D. H., Sondorp, H. E., Moody, A. H., Bryceson, A. D. M., & Davidson, R. N. (1993) · The Journal of Infectious Diseases · doi:10.1093/infdis/168.3.715 · Cited by 124
Tolerance to drug-induced cell death favours the acquisition of multidrug resistance in Leishmania
Moreira, W., Leprohon, P., & Ouellette, M. (2011) · Cell Death and Disease · doi:10.1038/cddis.2011.83 · Cited by 112
Optimal Dosing of Miltefosine in Children and Adults with Visceral Leishmaniasis
Dorlo, T. P. C., Huitema, A. D. R., Beijnen, J. H., & de Vries, P. J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00292-12 · Cited by 111
Self-citationZufferey, R., Allen, S., Barron, T., Sullivan, D. R., Denny, P. W., de Almeida, I. C., Smith, D. F., Turco, S. J., Ferguson, M. A. J., & Beverley, S. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308063200 · Cited by 110
Coelho, A. C., Boisvert, S., Mukherjee, A., Leprohon, P., Corbeil, J., & Ouellette, M. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001512 · Cited by 109
Brachwitz, H., & Vollgraf, C. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00001-w · Cited by 103
Efficacy of Miltefosine for the Treatment of American Cutaneous Leishmaniasis
Vélez, I. D., López, L., Sánchez, X., Mestra, L., Rojas, C. A., & Rodríguez, E. (2010) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2010.10-0060 · Cited by 102
Thakur, C. P., Olliaro, P., Gothoskar, S. V., Bhowmick, S., Choudhury, B., Prasad, S., Kumar, M., & Verma, B. B. (1992) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/0035-9203(92)90150-b · Cited by 92
Lira, R., Contreras, L. M., Rita, R. M. S., et al. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.5.537 · Cited by 90
Liu, D., Zhang, T., Marshall, A. J., Okkenhaug, K., Vanhaesebroeck, B., & Uzonna, J. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901099 · Cited by 89
Phase II study of daily oral miltefosine (hexadecylphosphocholine) in advanced colorectal cancer
Planting, A. S. T., Stoter, G., & Verweij, J. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80142-x · Cited by 77
Designing and Reporting Clinical Trials on Treatments for Cutaneous Leishmaniasis
González, U., Pinart, M., Revéiz, L., Rengifo‐Pardo, M., Tweed, J., Macaya, A., & Alvar, J. (2010) · Clinical Infectious Diseases · doi:10.1086/655134 · Cited by 76
Relapse of Visceral Leishmaniasis after Miltefosine Treatment in a Nepalese Patient
Pandey, B. D., Pandey, K., Kaneko, O., et al. (2009) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2009.80.580 · Cited by 74
Distribution and metabolism of hexadecylphosphocholine in mice
Breiser, A., Kim, D. ‐., Fleer, E. A. M., et al. (1987) · Lipids · doi:10.1007/bf02535556 · Cited by 73
Smorenburg, C. H., Seynaeve, C., Bontenbal, M., Planting, A. S. T., SINDERMANN, H., & Verweij, J. (2000) · Anti-Cancer Drugs · doi:10.1097/00001813-200011000-00006 · Cited by 73
Verweij, J., Planting, A. S. T., van der Burg, M., & Stoter, G. (1992) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01211805 · Cited by 71
Lipases and Phospholipases in Drug Development
(2004) · Wiley eBooks · doi:10.1002/3527601910 · Cited by 62
Bianciardi, P., Brovida, C., Valente, M., Aresu, L., Cavicchioli, L., Vischer, C., Giroud, L., & Castagnaro, M. (2009) · Toxicologic Pathology · doi:10.1177/0192623309344088 · Cited by 60
Cummings, H., Barbi, J. J., Reville, P. K., Oghumu, S., Zorko, N. A., Sarkar, A., Keiser, T. L., Lu, B., Rückle, T., Varikuti, S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1110339109 · Cited by 53
Characterization and identification of suspected counterfeit miltefosine capsules
Dorlo, T. P. C., Eggelte, T. A., de Vries, P. J., & Beijnen, J. H. (2012) · The Analyst · doi:10.1039/c2an15641e · Cited by 47
Self-citationTong, Z., Widmer, F., Sorrell, T. C., Guse, Z., Jolliffe, K. A., Halliday, C. L., Lee, O. C., Kong, F., Wright, L. C., & Chen, W. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01382-06 · Cited by 45
Intestinal Absorption of Miltefosine: Contribution of Passive Paracellular Transport
Menez, C., Buyse, M., Dugave, C., Farinotti, R., & BARRATT, G. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-006-9170-7 · Cited by 41
Phase II study of oral miltefosine in patients with squamous cell head and neck cancer
Verweij, J., Planting, A. S. T., Stoter, G., Gandía, D., & Armand, J. (1993) · European Journal of Cancer · doi:10.1016/s0959-8049(05)80369-7 · Cited by 41
Synthesis, antifungal and antimicrobial activity of alkylphospholipids
Obando, D., Widmer, F., Wright, L. C., Sorrell, T. C., & Jolliffe, K. A. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.05.028 · Cited by 36
Pentamidine Dosage: A Base/Salt Confusion
Dorlo, T. P. C., & Kager, P. A. (2008) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0000225 · Cited by 35
Self-citationWeingärtner, A., Drobot, B., Herrmann, A., Sánchez‐Cañete, M. P., Gamarro, F., Castanys, S., & Pomorski, T. G. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012443 · Cited by 35
Menez, C., Buyse, M., Farinotti, R., & BARRATT, G. M. (2007) · Lipids · doi:10.1007/s11745-007-3026-8 · Cited by 34
History of Kala-Azar in India.
Gupta, P. C. S. (1947) · PubMed · Cited by 34
A Poor-Quality Generic Drug for the Treatment of Visceral Leishmaniasis: A Case Report and Appeal
Dorlo, T. P. C., Eggelte, T. A., Schoone, G. J., de Vries, P. J., & Beijnen, J. H. (2012) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0001544 · Cited by 32
Self-citationHexadecylphosphocholine interferes with the intracellular transport of cholesterol in HepG2 cells
Carrasco-Jimenez, M. P., Jiménez‐López, J. M., Segovia, J. L., & Marco, C. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06322.x · Cited by 19
Chakrabandhu, K., Huault, S., & Hueber, A. (2008) · FEBS Letters · doi:10.1016/j.febslet.2008.11.019 · Cited by 17
Edwards, T., Omollo, R., Khalil, E. A. G., Yifru, S., Younis, B. M., Musa, A. M., Wasunna, M. K., Smith, P. G., Royce, C., Ellis, S., et al. (2011) · Trials · doi:10.1186/1745-6215-12-66 · Cited by 13
Self-citation
Cited by
Drug resistance and treatment failure in leishmaniasis: A 21st century challenge
Ponte-Sucre, A., Gamarro, F., Dujardin, J.-C., Barrett, M. P., López-Vélez, R., García-Hernández, R., Pountain, A. W., Mwenechanya, R., & Papadopoulou, B. (2017) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0006052 · Cited by 962
AKT as a Therapeutic Target for Cancer
Song, M., Bode, A. M., Dong, Z., & Lee, M.-H. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2738 · Cited by 782
Aronson, N., Herwaldt, B. L., Libman, M., Pearson, R., Lopez-Velez, R., Weina, P., Carvalho, E. M., Ephros, M., Jeronimo, S., & Magill, A. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw670 · Cited by 458
Kindrachuk, J., Ork, B., Hart, B. J., Mazur, S., Holbrook, M. R., Frieman, M. B., Traynor, D., Johnson, R. F., Dyall, J., Kuhn, J. H., et al. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03659-14 · Cited by 407
Drug repurposing and human parasitic protozoan diseases
Andrews, K. T., Fisher, G., & Skinner-Adams, T. S. (2014) · International Journal for Parasitology: Drugs and Drug Resistance · doi:10.1016/j.ijpddr.2014.02.002 · Cited by 383
Metadata
- Authors
- Dorlo, T. P. C., Balasegaram, M., Beijnen, J. H., & de Vries, P. J.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-07-24
- Volume
- 67
- Issue
- 11
- Pages
- 2576-2597
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2126420606
- Cited by
- 775
- References
- 65
- FWCI
- 36.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.